Canada · Delayed Price · Currency is CAD Rapid Dose Therapeutics Statistics
Total Valuation
CSE:DOSE has a market cap or net worth of CAD 12.28 million. The enterprise value is 18.07 million.
| Market Cap | 12.28M |
| Enterprise Value | 18.07M |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:DOSE has 136.44 million shares outstanding. The number of shares has increased by 5.68% in one year.
| Current Share Class | 136.44M |
| Shares Outstanding | 136.44M |
| Shares Change (YoY) | +5.68% |
| Shares Change (QoQ) | -0.32% |
| Owned by Insiders (%) | 15.19% |
| Owned by Institutions (%) | n/a |
| Float | 115.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.77 |
| PB Ratio | -1.63 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 58.29 |
| P/OCF Ratio | 58.29 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 85.77 |
Financial Position
The company has a current ratio of 0.04
| Current Ratio | 0.04 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 27.56 |
| Interest Coverage | -1.49 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.30% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 33.87% |
| Weighted Average Cost of Capital (WACC) | 5.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.72 |
| Inventory Turnover | 6.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.57% in the last 52 weeks. The beta is -0.91, so CSE:DOSE's price volatility has been lower than the market average.
| Beta (5Y) | -0.91 |
| 52-Week Price Change | -48.57% |
| 50-Day Moving Average | 0.10 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 40.84 |
| Average Volume (20 Days) | 36,929 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CSE:DOSE had revenue of CAD 2.58 million and -3.17 million in losses. Loss per share was -0.02.
| Revenue | 2.58M |
| Gross Profit | 1.28M |
| Operating Income | -1.89M |
| Pretax Income | -3.17M |
| Net Income | -3.17M |
| EBITDA | -1.82M |
| EBIT | -1.89M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 14,653 in cash and 5.81 million in debt, with a net cash position of -5.79 million or -0.04 per share.
| Cash & Cash Equivalents | 14,653 |
| Total Debt | 5.81M |
| Net Cash | -5.79M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -7.54M |
| Book Value Per Share | -0.06 |
| Working Capital | -8.39M |
Cash Flow
| Operating Cash Flow | 210,688 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 72,357 |
| Net Borrowing | 109,115 |
| Free Cash Flow | 210,688 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 49.83%, with operating and profit margins of -73.59% and -123.09%.
| Gross Margin | 49.83% |
| Operating Margin | -73.59% |
| Pretax Margin | -123.09% |
| Profit Margin | -123.09% |
| EBITDA Margin | -70.78% |
| EBIT Margin | -73.59% |
| FCF Margin | 8.18% |
Dividends & Yields
CSE:DOSE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.68% |
| Shareholder Yield | -5.68% |
| Earnings Yield | -25.81% |
| FCF Yield | 1.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CSE:DOSE has an Altman Z-Score of -24.98 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -24.98 |
| Piotroski F-Score | 2 |